Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU
According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics, Inc., has recently announced that the European Commission has given the company's investigational drug candidate mirdametinib Orphan Drug designation.…